PT217

Business news, market intelligence, and global industry analysis.

The Latest

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?

Representative image of a motorway corridor and capital flows illustrating HICL Infrastructure PLC’s £311 million A63 Motorway stake sale in France, as the London-listed infrastructure investor exits the Atlandes asset at a 21% premium to book value.

HICL Infrastructure (LSE: HICL) to sell A63 Motorway stake for £311m at 21% premium to book value

Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?

Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma

Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with…

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

August 18, 2024